| AGAT | Arginine–glycine amidinotransferase |
| ALS | Amyotrophic lateral sclerosis |
| ALSFRS-R | Amyotrophic lateral sclerosis functional rating scale (revised) |
| AUC | Area under the curve |
| ATP | Adenosine triphosphate |
| BBB | Blood–brain barrier |
| BCRP | Breast cancer resistance protein |
| CMC | Chemistry, Manufacturing, and Controls |
| CNS | Central nervous system |
| CrT | Creatine transporter |
| CrTD | Creatine transporter deficiency |
| CSF | Cerebrospinal fluid |
| DCE | Dodecyl creatine ester |
| DHA | Docosahexaenoic acid |
| DTE | Drug targeting efficiency |
| DTP | Direct NtB percentage |
| EEG | Electroencephalogram |
| fMRI | Functional MRI |
| GAMT | Guanidinoacetate methyltransferase |
| GLUT | Glucose transporter |
| GRAS | Generally recognized as safe |
| GSPR | General safety and performance requirement |
| iDDC | Integral drug-device combination |
| IN | Intranasal |
| IV | Intravenous |
| LFP | Local field potential |
| MCT | Monocarboxylate transporter |
| MDR | Medical device regulation |
| MRI | Magnetic resonance imaging |
| MRP | Multidrug resistance-associated protein |
| NHP | Non-human primate |
| NOAEL | No observed adverse effect level |
| NORD | National Organization for Rare Disorders |
| NtB | Nose-to-brain |
| NtN | Nose-to-neurons |
| PBPK | Physiologically based pharmacokinetic modelling |
| P-gp | P-glycoprotein |
| PEG | Polyethylene glycol |
| PSD | Particle size distribution |
| PET | Positron emission tomography |
| qEEG | Quantitative EEG |
| SPECT | Single photon emission computed tomography |
| WGA | Wheat germ agglutinin |